PMID- 38011484
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231129
IS  - 2717-011X (Electronic)
IS  - 2717-011X (Linking)
VI  - 21
IP  - 2
DP  - 2022 Apr 4
TI  - The association between body mass index, demographic and clinical characteristics 
      with cognitive performance in patients with neuromyelitis optica spectrum 
      disorder.
PG  - 74-82
LID - 10.18502/cjn.v21i2.10490 [doi]
AB  - Background: Cognitive dysfunction is one of the problems that patients with 
      neuromyelitis optica spectrum disorder (NMOSD) suffer from. We aimed to assess 
      the association between demographic and clinical features as well as body mass 
      index (BMI) and cognitive function in patients with NMOSD. Methods: A 
      cross-sectional study was performed on 41 patients with definite diagnosis of 
      NMOSD. Serum status of neuromyelitis optica immunoglobulin G (NMO-IgG) was 
      determined using enzyme-linked immunosorbent assay (ELISA) method. Cognitive 
      function was assessed by Minimal Assessment of Cognitive Function in Multiple 
      Sclerosis (MACFIMS) battery which is validated for Persian people before and 
      North American Adult Reading Test (NAART). Results: The mean score of NAART test 
      was higher in participants with normal weight compared with overweight patients 
      (40.47 +/- 3.51 vs. 36.00 +/- 5.74, P = 0.02). Current age was negatively correlated 
      with Delis-Kaplan Executive Function System (D-KEFS)-Sorting (P = 0.05, r = 
      -0.30). The correlation of duration of disease and cognitive performance was not 
      significant (P > 0.05). Higher physical disability based on Expanded Disability 
      Status Scale (EDSS) was correlated with lower results in Brief Visuospatial 
      Memory Test-Revised (BVMT-R) (P < 0.01, r = -0.50), California Verbal Learning 
      Test-second edition (CVLT-II)-Delayed Recall (P = 0.02, r = -0.35), and Symbol 
      Digit Modalities Test (SDMT) (P = 0.03, r = -0.33) subtests of MACFIMS. Annual 
      relapse rate was indirectly correlated with CVLT-II (P = 0.03, r = -0.34) and 
      CVLT-II-Delayed Recall (P = 0.01, r = -0.38). Male participants obtained better 
      scores in Paced Auditory Serial Addition Test (PASAT) subtest (P = 0.05). NMO-IgG 
      seropositive patients had poorer performance in terms of CVLT-II-Delayed Recall, 
      Controlled Oral Word Association Test (COWAT), and D-KEFS-Descriptive (P < 0.05). 
      Participants with bachelor and master education degrees showed significantly 
      better results compared to those with high school degree (P < 0.05). Conclusion: 
      Investigating the clinical and demographic factors affecting cognitive impairment 
      can increase the awareness of health care providers for early diagnosis of 
      cognitive impairment in patients with NMOSD and increase the quality of health 
      services.
CI  - Copyright (c) 2022 Iranian Neurological Association, and Tehran University of 
      Medical Sciences Published by Tehran University of Medical Sciences.
FAU - Rezaeimanesh, Nasim
AU  - Rezaeimanesh N
AD  - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Saeedi, Roghayyeh
AU  - Saeedi R
AD  - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Sahraian, Mohammad Ali
AU  - Sahraian MA
AD  - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Ghadiri, Fereshteh
AU  - Ghadiri F
AD  - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Naser Moghadasi, Abdorreza
AU  - Naser Moghadasi A
AD  - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of 
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Curr J Neurol
JT  - Current journal of neurology
JID - 101769679
PMC - PMC9860205
OTO - NOTNLM
OT  - Neuromyelitis Optica; Cognition; Body Mass Index; Demography
EDAT- 2022/04/04 00:00
MHDA- 2022/04/04 00:01
PMCR- 2022/04/04
CRDT- 2023/11/27 15:00
PHST- 2021/11/25 00:00 [received]
PHST- 2022/02/02 00:00 [accepted]
PHST- 2022/04/04 00:01 [medline]
PHST- 2022/04/04 00:00 [pubmed]
PHST- 2023/11/27 15:00 [entrez]
PHST- 2022/04/04 00:00 [pmc-release]
AID - CJN-21-74 [pii]
AID - 10.18502/cjn.v21i2.10490 [doi]
PST - ppublish
SO  - Curr J Neurol. 2022 Apr 4;21(2):74-82. doi: 10.18502/cjn.v21i2.10490.